Premium
Rituximab‐induced acute liver failure after an allogeneic transplantation for chronic myeloid leukemia
Author(s) -
Qazilbash Muzaffar H.,
Qu Zhenhong,
Hosing Chitra,
Couriel Daniel,
Donato Michele,
Giralt Sergio,
Champlin Richard
Publication year - 2005
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.20413
Subject(s) - medicine , rituximab , autoimmune hemolytic anemia , myeloid leukemia , cd20 , hematopoietic stem cell transplantation , immunology , transplantation , anemia , gastroenterology , leukemia , antibody
Autoimmune hemolytic anemia (AIHA) is a well‐recognized complication of allogeneic bone marrow transplantation (BMT) and can affect up to 5% patients. Several recent case reports suggested the efficacy of anti‐CD20 monoclonal antibody, rituximab, in treating this condition. We report our experience with a 21‐year‐old female with accelerated‐phase chronic myeloid leukemia who underwent allogeneic hematopoietic stem cell transplantation from a matched, unrelated donor. The patient developed autoimmune hemolytic anemia that failed to respond to steroids, intravenous immunoglobulins, and plasma exchange. She was then treated with rituximab that resulted in fatal acute liver toxicity. Am. J. Hematol. 80:43–45, 2005. © 2005 Wiley‐Liss, Inc.